• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC CORPORATION ELUVIATM DRUG-ELUTING VASCULAR STENT SYSTEM; STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC CORPORATION ELUVIATM DRUG-ELUTING VASCULAR STENT SYSTEM; STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING Back to Search Results
Model Number 24620
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Reocclusion (1985); Discomfort (2330)
Event Date 09/20/2018
Event Type  Injury  
Manufacturer Narrative
Device is a combination product.
 
Event Description
The patient was enrolled in (b)(6) study.It was reported that in-stent restenosis occurred.On (b)(6) 2016, the index procedure was performed.The target lesion was located in the right distal superficial femoral artery (sfa) extending to the proximal popliteal artery.The target lesion was 80% stenosed and was 40mm long with a proximal reference vessel diameter of 6.00mm and a distal vessel diameter of 6.00mm, and was classified as a tasc ii a lesion.The target lesion was treated with pre-dilatation and a 7mm x 60mm eluvia stent was placed.The lesion was then post-dilated and residual stenosis was 0%.On (b)(6) 2018, the patient experienced sudden onset of right calf discomfort.On (b)(6) 2018, the patient presented to the hospital, stating the symptoms occurred while walking short distances indoors, and was relieved by rest.An ultrasound was performed which revealed in-stent restenosis (isr) of the eluvia stent.On (b)(6) 2018, the patient presented to the hospital again for intervention.Angiography confirmed the in-stent restenosis, showing that the distal sfa was 100% stenosed and the proximal popliteal artery had 100% isr.The isr was treated using laser atherectomy and balloon angioplasty with two non-bsc balloons.The lesion in the distal sfa was further treated by implantation of a non-bsc drug coated stent.The proximal right sfa was treated with drug coated balloon angioplasty.Post procedure, the angiographic results were excellent.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ELUVIATM DRUG-ELUTING VASCULAR STENT SYSTEM
Type of Device
STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING
Manufacturer (Section D)
BOSTON SCIENTIFIC CORPORATION
two scimed place
maple grove MN 55311
Manufacturer (Section G)
BOSTON SCIENTIFIC SCIMED, INC
two scimed place
maple grove MN 55311
Manufacturer Contact
sonali arangil
two scimed place
maple grove, MN 55311
6515827403
MDR Report Key7951939
MDR Text Key123246925
Report Number2134265-2018-61762
Device Sequence Number1
Product Code NIU
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P180011
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,health
Reporter Occupation Physician
Type of Report Initial
Report Date 10/10/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date01/31/2017
Device Model Number24620
Device Catalogue Number24620
Device Lot Number18334951
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 09/28/2018
Initial Date FDA Received10/10/2018
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured09/01/2015
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age72 YR
-
-